Chemed Corporation (CHE) Fair Value 2026

CHE · Medical Care Facilities ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.2 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-08-27, Chemed Corporation (CHE) trades at $520.27, versus a $376.73 median fair value across its 9 active models — 27.6% below the current price. QOC: 8.2/10. Value Trap Risk: 6/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $483.05.

Key Facts

Ticker
CHE
Price
$520.27
Quality Score
8.2/10
Value Trap Risk
6/100
Models Active
9/13
Last Updated
Strength: Quality Score of 8.2/10 indicates strong fundamentals
Risk: Majority of models suggest overvaluation

Is Chemed Corporation (CHE) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Chemed Corporation (CHE) appears overvalued as of : the median of 9 independent fair value estimates is $376.73, 27.6% below the current price of $520.27. Estimates range from $136.94 to $519.72. CHE scores 8.2/10 on fundamental quality and 6/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CHE’s -27.6% gap is wider than that market norm, and the Medical Care Facilities sector median is -28.6%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Chemed Corporation Stock in 2026? →

What Fair Value Does Each Model Give CHE?

9 Intrinsic Value Models vs. Current Price ($520.27)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $483.05 -7.2%
Intrinsic · High Conviction
 $300.98 -42.1%
Ensemble · Medium Conviction
 $376.73 -27.6%
Intrinsic · High Conviction
 $136.94 -73.7%
Unlock the Full Matrix

Access 5 additional models including Markov DDM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is CHE's Fair Value Range?

Spread across 9 independent models · $136.94 to $519.72

CirclFi's 9 active models place Chemed Corporation (CHE) between $136.94 and $519.72 per share, a spread of 102% of the median. The median of that range — $376.73 — is the fair value CirclFi publishes for CHE, against a current price of $520.27.

Low · EROICHigh · Regime Cross
$136.94median $376.73$519.72
Where the range comes from
Most bearish modelEROIC Spread$136.94
Most bullish modelRegime Cross-Sectional$519.72
Model agreement0 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CHE. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CHE, not a CirclFi price target. How each model works →

What Is Chemed Corporation (CHE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Chemed Corporation's intrinsic value is estimated at $376.73. Trading at its current price of $520.27, the valuation engine raises significant caution: 7 of 9 models flag downside risk, projecting a median implied return of -27.6%. Notably, Regime Cross sees the most upside at -0.1% (fair value: $519.72), while EROIC is the most conservative at -73.7% ($136.94). The spread between these extremes — +73.6% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About CHE?

9 of 13 models are currently active for CHE. All 9 active models suggest the stock trades above fair value. Taken together, their median fair value for CHE is $376.73 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $483.05 on its own, implying -7.2% downside from the current price. See which stocks rank higher →

How Does CHE Rank in Medical Care Facilities?

Among 60 Medical Care Facilities stocks, CHE ranks #10 by Quality of Company score. CirclFi's QOC score of 8.2/10 evaluates 32 fundamental signals. A score of 8.2 places CHE in the top tier.

See all Most Undervalued Medical Care Facilities Stocks →

Chemed Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is CHE a Value Trap?

CirclFi's Value Trap algorithm assigns CHE a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Chemed Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Chemed Corporation earns a quality score of 8.2/10. This robust rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +73.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CHE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CHE's 9 active models, average confidence is 57%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Chemed Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Care Facilities Stocks Should You Also Analyze?

11 related Medical Care Facilities stocks with 13-model coverage

PNTGThe Pennant Group, Inc.QOC 8.3ARDTArdent Health, Inc.QOC 8.2THCTenet Healthcare CorporationQOC 8.3USPHU.S. Physical Therapy, Inc.QOC 7.9NUTXNutex Health Inc.QOC 8.4HCAHCA Healthcare, Inc.QOC 7.9ASTHAstrana Health, Inc.QOC 7.1GBCSSelectis Health, Inc.QOC 5.9FOXOFOXO Technologies Inc.QOC 3.9ADUSAddus HomeCare CorporationQOC 8.9NHCNational HealthCare CorporationQOC 8.7

Read investment analysis: PNTG · ARDT · THC · USPH · NUTX · HCA · ASTH · GBCS · FOXO · ADUS · NHC

Which Other Stocks Have a Similar Quality Score to CHE?

7 companies across all industries closest to CHE’s Quality of Company score of 8.2/10.

ABEVAmbev S.A.QOC 8.2VRRMVerra Mobility CorporationQOC 8.2GRNTGranite Ridge Resources, Inc.QOC 8.2NBBKNB Bancorp, Inc.QOC 8.2TXNTexas Instruments IncorporatedQOC 8.2ZSZscaler, Inc.QOC 8.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ABEV · VRRM · GRNT · NBBK · TXN · ZS · NVDA

Where Does CHE Sit in CirclFi's Medical Care Facilities Rankings?

CHE is ranked against every other Medical Care Facilities stock CirclFi covers in each of these screens.

See all Medical Care Facilities stocks ranked →

What Else Do Investors Ask About Chemed Corporation’s Valuation?

What is Chemed Corporation's intrinsic value in 2026?

CirclFi puts Chemed Corporation (CHE)'s intrinsic value at $376.73 — the median of 9 independent model estimates as of 2026-08-27, ranging from $136.94 to $519.72. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $483.05 on its own. The Quality of Company score is 8.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CHE overvalued or undervalued right now?

At $520.27, 0 of 9 active models suggest CHE may be undervalued, while 9 indicate potential overvaluation. The median of all 9 fair value estimates is $376.73, 27.6% below the current price of $520.27 — a consensus view that CHE is overvalued. The assessment depends on which methodology best fits Chemed Corporation's business model in Medical Care Facilities.

What does a Quality of Company score of 8.2 mean for CHE?

Chemed Corporation's QOC of 8.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on CHE?

CirclFi analyzes CHE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CHE?

Of the 9 models currently active on CHE, Regime Cross-Sectional is the most bullish at $519.72 per share, and EROIC Spread is the most bearish at $136.94. CirclFi's published fair value for CHE is the median of that range, $376.73, not either extreme. The gap between the two ends equals 102% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CHE a value trap in 2026?

Chemed Corporation's Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Chemed Corporation (CHE) has a median fair value of $376.73 — 27.6% below the current price of $520.27 — as of 2026-08-27.” Source: circlfi.com/stock/CHE/ · Methodology
Primary sources for this CHE valuation
  • Financial statements: Chemed Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000019584) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CHE as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on CHE.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for CHE Unlock All 9 — $39/mo